Latest News - Amgen
Top Corporates Hub
Amgen
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
09.06.2026 11:00
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the election of Keith Leonard as Chairman of its Board of Directors. Keith is a highly experienced global biopharmaceutical executive with 30 years of industry experience leading companies and driving commercial strategies. Throughout h
Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating
09.06.2026 03:38
With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed […]
Assessing Whether Amgen (AMGN) Is Slightly Undervalued After Recent Share Price Gains
06.06.2026 04:24
Amgen stock snapshot and recent performance Amgen (AMGN) is drawing attention after recent price moves, with the stock last closing at US$349.58. Over the past month it gained about 5.6%, while over the past 3 months it declined roughly 5.4%. See our latest analysis for Amgen. The recent 1-day share price return of 1.15% and 7-day return of 3.8% build on a 30-day share price gain of 5.6%, while the 1-year total shareholder return of 24% and 3-year total shareholder return of about 75% point...
Is Oncology Approval And Autoimmune Data Momentum Altering The Investment Case For Amgen (AMGN)?
05.06.2026 14:18
Amgen recently received European Commission approval for IMDYLLTRA (tarlatamab) to treat adults with extensive-stage small cell lung cancer after platinum-based chemotherapy and presented fresh Phase 3 and real-world data on UPLIZNA and TAVNEOS at the EULAR 2026 Congress, reinforcing their safety and disease-control profiles in rare autoimmune conditions. Together, the new oncology authorization and autoimmune data highlight Amgen’s growing presence in high unmet-need niches, where...
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
05.06.2026 05:02
Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial
Stock Market Today: Dow Rises, Nasdaq Falls With Jobless Data Due; Broadcom, CrowdStrike Plunge (Live Coverage)
04.06.2026 12:06
Stock Market Today: The Dow Jones index rose Thursday ahead of jobless claims. Broadcom and CrowdStrike plunged on earnings.
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture
02.06.2026 15:28
As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
02.06.2026 15:15
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
02.06.2026 13:57
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The […]
How The Amgen (AMGN) Story Is Evolving As Rare Disease Upside Meets Valuation Caution
01.06.2026 05:06
Amgen's fair value estimate has been nudged from US$349.66 to US$352.23 per share, a small move that still matters if you are tracking entry points and valuation ranges. Around that level, analysts are split, with some using higher targets such as US$427 on the back of rare disease and pipeline assets, while others sit closer to US$350 and stress that recent gains already price in a lot of the good news. Read on to see how to interpret these shifting targets and keep up with the evolving...
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?
31.05.2026 08:26
Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects
Amgen Stock: Is AMGN Outperforming the Healthcare Sector?
31.05.2026 07:25
Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Possible Bearish Signals With Amgen Insiders Disposing Stock
28.05.2026 12:00
Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...
Amgen (AMGN) Announces Retirement of CFO Peter Griffith
25.05.2026 19:54
Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]
CFOs On the Move: Week ending May 22
22.05.2026 08:49
Amgen names a new chief financial officer, Thales hires Nissan’s former CFO and Rent the Runway’s finance chief tenders his resignation.
A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
22.05.2026 06:15
Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient deaths in Japan, prompted regulators and partners to restrict new prescriptions and consider withdrawal in the U.S. See our latest analysis for Amgen. At a share price of $337.42, Amgen has seen its 90 day share price return fall 9.96%, even as its 1 year total shareholder return of 27.83% and 3 year total shareholder return of 70.14% point to stronger longer term...
Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
21.05.2026 08:51
Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432. The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth […]
Amgen : Statement on TAVNEOS® (avacopan)
16.05.2026 00:37
Amgen Statement on TAVNEOS® On May 15, 2026, media outlets reported 20 deaths associated with patients being treated with TAVNEOS® in Japan. The report was based on a regulatory...
Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
15.05.2026 09:19
Market opportunities for Romiplate are driven by the increasing diagnosis of immune thrombocytopenia (ITP), expansion into additional thrombocytopenia conditions, strong commercial sales, global expansion, and growing physician adoption. These factors support its anticipated growth through 2034 in major global markets.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Romiplate Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides ins
How The Amgen (AMGN) Investment Story Is Shifting With New Guidance And Pipeline Updates
15.05.2026 09:13
The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment fits with recent analyst commentary, where higher and lower price targets have been clustering around the current trading range as views on growth and execution remain mixed. As you read on, you will see how to track these changing signals and what they might mean for following Amgen’s evolving story over time. Stay...